Precision Medicines Against
LIpid-MEdiated Targets

Lime Therapeutics is the lipids company.

We are a fast-growing biotechnology company focused on making a difference for patients. We are using our breakthrough LipidSense™ platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders.

Intro

Leadership

Team

Shardule Shah, PhD, MBA

Co-Founder and CEO

View Bio

Prakrit Jena, PhD

Co-Founder and CTO

View Bio

Mariluz Soula, PhD

Scientist II

View Bio

Scientific and Chemistry Advisory Board

Robert Schwartz, MD, PhD

Weill Cornell Medicine

Matthew
Vander Heiden, MD, PhD

Massachusetts Institute of Technology (MIT)

Rushika Perera, PhD

University of California,
San Francisco

Tuomas Tammela, MD, PhD

Memorial Sloan Kettering Cancer Center

Xuejun Jiang, PhD

Memorial Sloan Kettering Cancer Center

Francis Tavares, PhD

ChemoGenics BioPharma

Business Advisors

Robin Mansukhani

CEO, Deciduous Therapeutics

Jeff Hatfield, MBA

Chairman of the Board of Directors, Vividion Therapeutics and ROME Therapeutics

Team

SAB

Biz Advisors

Technology

Creating Lipid-Altering Therapeutics

Lipid dysfunction is a hallmark of a broad range of diseases such as cancer, metabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. Despite this, efforts to hunt for lipid-mediated targets and create novel therapies have remained elusive due to lack of technology.

We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a high-throughput screening format, and in live animals.

We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in metabolic diseases and neurodegenerative disorders.

Ultimately, we are exploring therapeutic opportunities to touch the lives of 100 million patients.